Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF 77 3-Year FCF Growth Rate is 30.10% as of Dec. 2025, which is 58% above its 10-year median of 19.10. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 583 Medical Devices & Instruments companies, NIOX Group ranks better than 64.15% on this metric.
During the past 12 months, NIOX Group's average Free Cash Flow per Share Growth Rate was -8.30% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 30.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of NIOX Group was 128.90% per year. The lowest was -43.10% per year. And the median was 19.10% per year.
NIOX Group (OTCPK:CSSPF) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
NIOX Group 3-Year FCF Growth Rate Related Terms
CSSPF vs ABT, SYK, MDT: 3-Year FCF Growth Rate Comparison
For the Medical Devices subindustry, NIOX Group's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where NIOX Group's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 30.10% mean?
NIOX Group (CSSPF) has a 3-Year FCF Growth Rate of 30.10% as of Dec. 2025. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for NIOX Group and its competitors. This is 58% above median its historical median of 19.10. According to the industry distribution chart, NIOX Group ranks #209 out of 583 companies in the Medical Devices & Instruments industry, placing it in the top 35.8%.
Is NIOX Group's 3-Year FCF Growth Rate too high?
NIOX Group's current 3-Year FCF Growth Rate of 30.10% is 58% above median its 10-year median of 19.10. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 17.60. NIOX Group's value of 30.10% is 71% above this industry median. Based on the distribution chart, NIOX Group ranks #209 out of 583 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's 3-Year FCF Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #209 out of 583 companies for 3-Year FCF Growth Rate. This puts NIOX Group in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 17.60. NIOX Group's value of 30.10% is 71% above this benchmark. While the company's 10-year median is 19.10 vs. the industry median of 17.60, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 17.60, based on 583 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current 3-Year FCF Growth Rate of 30.10% is 71% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 17.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current 3-Year FCF Growth Rate is 30.10%, which is 58% above median its own 10-year median of 19.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.82 — trading 32.2% below its estimated fair value. The current 3-Year FCF Growth Rate is 30.10%, which is 58% above median its 10-year median of 19.10 and 71% above the Medical Devices & Instruments industry median of 17.60. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For NIOX Group (CSSPF), the current 3-Year FCF Growth Rate is 30.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.82 is trading 32.2% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
3-Year FCF Growth Rate: 30.10% (58% above median its 10-year median of 19.10)
GF Value™: $1.21 vs. price of $0.82 (32.2% below fair value)
Industry Position: 71% above the Medical Devices & Instruments median (#209 of 583)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
